Canada Foundation for Innovation Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2009
NCT02150434
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

raav2.rep1 (1 trial)

Drugs in Other Trials (1)

oxygen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroideremia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2